AMP002 Phase III Contraceptive Study

Summary

This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.

Timeline

Start

2017-07-24

Primary completion

2018-11-29

Completion

2018-11-29

Outcome

Met primary endpoint

release “its Phase 3 clinical trial of Amphora® for the prevention of pregnancy, AMPOWER, successfully met its primary endpoint.” evofem.com ↗

Drugs

Indications

No indication recorded.